Global Hemostatic Agents Market - 2025 - 2032

Global Hemostatic Agents Market - 2025 - 2032

The global hemostatic agents market reached US$ 3.01 billion in 2024 and is expected to reach US$ 4.15 billion by 2032, growing at a CAGR of 4.2% during the forecast period 2025-2032.

Hemostatic agents are substances designed to help prevent or stop bleeding at a wound or surgical site. They work by facilitating the natural processes that occur during hemostasis, which is the body's mechanism for stopping bleeding. Hemostatic agents interact with plasma proteins, calcium ions, and blood platelets to promote clot formation and control bleeding.

Hemostatic agents enhance this fibrinogen-to-fibrin conversion, ensuring a more efficient and durable clot. These agents are commonly used in surgical settings, trauma care, and during medical procedures where bleeding control is critical, providing a crucial aid in promoting faster and more reliable hemostasis.

Market Dynamics: Drivers & Restraints

Increasing Surgical Volume

The growing number of surgical procedures worldwide is a key factor driving the hemostatic agents market. As surgical volumes rise, there is an increasing need for effective hemostatic agents to control bleeding during complex surgeries. This trend is further fueled by the rising prevalence of chronic conditions, such as cardiovascular diseases and cancer, that often require surgical treatment. For instance, the National Institute of Health in 2023 stated that almost 400,000 CABG surgeries are performed each year making it the most commonly performed major surgical procedure.

As more patients undergo surgery, the demand for reliable hemostatic solutions continues to grow, contributing to the market's expansion. For instance, according to the National Institute of Health in 2024, total hip and knee arthroplasty surgeries are two of the most common procedures performed in the United States, with an estimated 7 million Americans living with a total hip or knee replacement and over 1 million total hip and knee replacements performed each year.

Hemostatic agents, such as gels, dressings, and powders, are increasingly being used to support hemostasis in these procedures, making them an essential component in modern surgical practices. The need for effective hemostasis, especially in surgeries requiring high precision and quick recovery, is making these agents important components in surgeries. Thus, as surgical techniques continue to evolve and surgical volumes increase worldwide, the market for hemostatic agents is expected to expand rapidly

Adverse Effects Associated with the Hemostatic Agents

Adverse effects associated with hemostatic agents pose a significant challenge to their market growth, raising concerns about patient safety and treatment effectiveness. These agents can lead to various side effects, including headaches, nausea, respiratory issues, and potentially severe allergic reactions such as anaphylaxis, which may discourage healthcare providers from using them. Furthermore, complications like infections and tissue damage can occur from improper application or overuse of these products, complicating surgical outcomes and limiting their broader adoption.

Segment Analysis

The global hemostatic agents market is segmented based on material, form, route of administration, application, end-user, and region.

Type:

Chitosan-based segment is expected to dominate the global hemostatic agents market share

Chitosan-based hemostatic agents segment is expected to hold a dominant position in the hemostatic agents market due to several key factors. Chitosan's unique biocompatibility, tunable mechanical properties, and ease of handling make it an ideal choice for use in hemostatic applications. Its injectability allows for minimally invasive procedures, which enhances its appeal in various surgical settings.

Chitosan-based hemostatic hydrogels are commonly used for controlling bleeding due to their exceptional biocompatibility, adjustable mechanical properties, injectability, and ease of use. Additionally, chitosan (CS) can absorb red blood cells and stimulate platelet activation, enhancing the process of hemostasis. The growing demand for natural and biocompatible materials in healthcare, along with its proven efficacy in controlling bleeding during surgeries, positions chitosan-based hemostatic agents as a leading solution in the market. Additionally, advancements in chitosan-based formulations are further driving the segment’s growth, making it a preferred choice for healthcare providers.

Geographical Analysis

North America is expected to hold a significant position in the global hemostatic agents market share

North America is expected to hold a significant position in the global hemostatic agents market due to several high rates of surgical procedures which include both elective and emergency surgeries, leading to higher demand for hemostatic agents to control bleeding during and after these procedures. For instance, according to the National Institute of Health report in 2023, in the United States, 1 in 9 individuals living in households reported having at least one surgical procedure in 2023. The highest rates were observed among individuals aged 65 and older, as well as Medicare beneficiaries, with approximately 1 in 5 people in both groups reporting having undergone surgery.

The growing prevalence of chronic conditions like cardiovascular diseases, diabetes, and cancer, all which increase the demand for effective hemostatic solutions. Furthermore, North America comprises several key market players and a strong focus on medical innovation, leading to the development and adoption of cutting-edge hemostatic products. For instance, in July 2023, Baxter International Inc. launched the PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding. The region also has well-established regulatory frameworks, which ensure the safety and effectiveness of these agents, further boosting their use.

Competitive Landscape

The major global players in the hemostatic agents market include Becton, Dickinson, and Company, Aegis Lifesciences, Baxter, Teleflex Incorporated, Johnson & Johnson Services, Inc., Pfizer Inc., 3-D Matrix Medical Technology, Medcura, Ferrosan Medical Devices A/S and Delta Surgical among others.

Key Developments
• In April 2023, Olympus announced the launch of EndoClot Adhesive (ECA), EndoClot Polysaccharide Hemostatic Spray (PHS) and EndoClot Submucosal Injection Solution (SIS) in the Europe, Middle East and Africa (EMEA) region. This innovative portfolio was developed by EndoClot Plus, Inc. (EPI), which expanded its distribution agreement with Olympus from the U.S. to EMEA in December 2022.
• In September 2024, Toagosei Co., Ltd. launched a dental hemostatic agent for tooth extraction sockets called “Aron Cure Dental”. Aron Cure Dental is a new concept of dental hemostatic agent. It stops bleeding after tooth extraction with a hydrogel polymer sponge.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Hemostatic Agents market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.